S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
David F. McDermott,Robert J. Motzer,Michael B. Atkins,Elizabeth R. Plimack,Mario Sznol,Saby George,Charles G. Drake,Brian I. Rini,Toni K. Choueiri,Timothy M. Kuzel,Jeffrey A. Sosman,David Smith,Ulka N. Vaishampayan,John D. Powderly,Suzanne L. Topalian,Huanyu Zhao,Ian M. Waxman,Hans J. Hammers +17 more
TL;DR: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, was recently approved by the FDA for patients with clear-cell aRCC previously treated with anti-angiogenic therap...
Journal ArticleDOI
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer
Ajjai Alva,Luke Nordquist,Stephanie Daignault,Saby George,Jorge Ramos,Costantine Albany,Sudhir Isharwal,Matthew McDonald,Gregory Campbell,Pongwut Danchaivijitr,Sarah Yentz,Aseem Anand,Evan Y. Yu +12 more
TL;DR: This work sought to identify potential clinical variables associated with outcomes after radium‐223 therapy in routine practice and found no clear relationships between therapy frequency and clinical outcomes.
Journal ArticleDOI
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan Basch,Mark C. Scholz,Johann S. de Bono,Nicholas J. Vogelzang,Paul de Souza,Gavin Marx,Ulka N. Vaishampayan,Saby George,James K. Schwarz,Emmanuel S. Antonarakis,Joe M. O'Sullivan,Arash Rezazadeh Kalebasty,Kim N. Chi,Robert Dreicer,Thomas E. Hutson,Amylou C. Dueck,Antonia V. Bennett,Erica Simone Dayan,Milan Mangeshkar,Jaymes Holland,Aaron Weitzman,Howard I. Scher +21 more
TL;DR: Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases and future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation.
Journal ArticleDOI
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
Robert J. Motzer,Padmanee Sharma,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Huanyu Zhao,Ian M. Waxman,Bernard Escudier +19 more
TL;DR: A phase III trial of NIVO vs EVE in previously treated patients with advanced or metastatic RCC was halted early as it met its endpoint; superior overall survival (OS) was seen with NIVo vs EVE.
Journal ArticleDOI
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Ethan Basch,Mark C. Scholz,Johann S. de Bono,Nicholas J. Vogelzang,Paul de Souza,Gavin Marx,Ulka N. Vaishampayan,Saby George,James K. Schwarz,Emmanuel S. Antonarakis,Joe M. O'Sullivan,Arash Rezazadeh Kalebasty,Kim N. Chi,Robert Dreicer,Thomas E. Hutson,Milan Mangeshkar,Jaymes Holland,Aaron Weitzman,Howard I. Scher +18 more
TL;DR: This double-blind, controlled phase 3 study compared the effects of Cabo versus MP on pain palliation in men with progressive mCRPC and found that the former was associated with improvements in pain, bone scans, measurable disease, and circulating tumor cells.